Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case
MMM syndrome is a rare but life-threatening complication of ICI therapy. Early recognition and multidisciplinary management are crucial. This case underscores the importance of weighing the risks and benefits of initiating immunotherapy and utilizing biomarker-driven clinical decisions.
Authors
- Michelle Greenman (ORCID: https://orcid.org/0000-0003-1809-1468)
- Masoud Azodi (ORCID: https://orcid.org/0000-0002-0570-8089)
- Jennifer M. Kwan (ORCID: https://orcid.org/0000-0002-4715-1848)
- Daniel DiCapua
- Blair McNamara
- Gary Altwerger (ORCID: https://orcid.org/0000-0002-2252-947X)
- John P. Mikhaiel
- Emily Daigle
- Yasmin Abozenah (ORCID: https://orcid.org/0009-0003-4470-8019)
Institutions
- Yale University (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1016/j.gore.2025.101950
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05